MedAdvisor Taps John Ciccio to Lead Next Growth Phase as CEO

Leadership Transition at MedAdvisor

MedAdvisor Limited, a leader in pharmacy-driven patient engagement solutions, has announced a significant executive change with the appointment of John Ciccio as its new CEO and Managing Director. Effective from 7 November 2025, Ciccio succeeds Rick Ratliff, who will remain involved in an advisory capacity to ensure a smooth handover. This leadership change comes at a pivotal moment as MedAdvisor approaches the final stages of a major technology transformation and seeks to expand its footprint in the competitive US healthcare technology market.

A Leader with Deep Company Roots

John Ciccio is no stranger to MedAdvisor, having spent 12 years with Adheris Health, the US business acquired by MedAdvisor in 2020. His tenure included serving as President and CEO from 2019 to 2022, during which he drove revenue growth from US$25 million to nearly US$40 million and launched the company’s intelligent patient management platform, THRiV. Ciccio’s extensive experience in healthcare technology and commercial strategy positions him well to lead MedAdvisor through its next chapter, building on the foundation laid by his predecessor.

Achievements Under Outgoing CEO Rick Ratliff

Rick Ratliff’s 3.5-year leadership saw MedAdvisor achieve several critical milestones, including the divestment of its ANZ business, the extinguishment of all debt obligations, and the expansion of its health program pipeline. Perhaps most notably, Ratliff spearheaded a major technology transformation initiative, dubbed Transformation 360, which is expected to culminate in early 2026 with the rollout of a next-generation engagement platform. This platform aims to provide MedAdvisor with a competitive edge in pharmacy workflow and patient engagement solutions.

Strategic Outlook and Remuneration Details

The board expressed confidence in Ciccio’s ability to navigate the evolving healthcare landscape, highlighting his integrity and proven track record. Ciccio’s remuneration package includes a fixed annual salary starting at USD 325,000, increasing to USD 425,000 by January 2027 contingent on performance hurdles, alongside a substantial options grant subject to shareholder approval. Notably, there is no short-term incentive component for the first 18 months, reflecting a focus on long-term value creation.

Looking Ahead

With Ciccio at the helm, MedAdvisor is poised to leverage its technological advancements and US market presence to drive growth. The transition signals a strategic emphasis on scaling the business and maximising shareholder value amid a dynamic industry environment. Investors and industry watchers will be keenly observing how Ciccio’s leadership shapes MedAdvisor’s trajectory in the coming months.